TAS-120-301(FOENIX-CCA3)
| Study Name | |
| TAS-120-301(FOENIX-CCA3) | |
| ClinicalTrials.gov Identifier (if applicable) | |
| NCT04093362 | |
| Clinical Trial Category (check all that apply) | |
|
|
| Study Center | |
| Institution Name | |
| Mayo Clinic | |
| City | |
| Phoenix | |
| State | |
| AZ | |
| Zip Code | |
| 85004 | |
| Country | |
| United States | |
| List additional Institutions (include address, phone number, and website) | |
| Please refer to the Clinical Trials. gov listing and contact the Taiho Help Line at clinicaltrialinfo@ for a site list |
|
| Study Contacts | |
| Principal Investigator | |
| Mitesh Borad, MD | |
| P.I. Phone | |
| (000) 000-0000 | |
| P.I. Email | |
| TBD@TBD.com | |
| List additional Principal Investigators (include phone number and email) | |
| Please refer to the Clinical Trials. gov listing and contact the Taiho Help Line at clinicaltrialinfo@ for a site list |
|
| Study Coordinator | |
| TBD | |
| Study Coordinator Phone | |
| (000) 000-0000 | |
| Study Coordinator Email | |
| TBD@TBD.com | |
| List additional Study Coordinators (include phone number and email) | |
| Please refer to the Clinical Trials. gov listing and contact the Taiho Help Line at clinicaltrialinfo@ for a site list |
|
| OVERVIEW – in layman’s terms (150 words max) | |
| FGFR2(fibroblast growth factor receptor 2) gene rearrangements, have been identified as an early driver of oncogenic events in approximately 15% of CCA patients. Futibatinib (TAS-120),an oral, highly selective, irreversible tyrosine kinase inhibitor (TKI) that inhibits FGFR1-4 isoforms, and have shown evidence of efficacy on CCA. |
|
| Enrollment | |
| 216 | |
| Study Start Date | |
| 08/07/2020 | |
| Estimated Completion Date | |
| 9/30/2023 (active, no longer recruiting as of 4/7/23) | |
| Purpose of the Study – in Layman’s Terms (use the “+” to add more list items) | |
|
|